63 results about "Neurodevelopmental disorder" patented technology

The present disclosure provides methods of treating a neurodevelopmental disorder (NDD) in a subject by administering a therapeutically effective amount of N-acetyl leucine.

Embodiments of the invention provide a solution for ameliorating microbiome effects on neurodevelopment by developing a probiotic composition for consumption by a female during gestation. In certain aspects the probiotic is a multi-strain probiotic cocktail consisting of immunomodulatory taxa and administered females during pregnancy and lactation.

The invention belongs to the technical field of nutritional compositions, and particularly relates to a composition, a preparation method thereof and application of the composition in protecting brain health. The composition provided by the invention is prepared from docosahexaenoic acid, 3-sialic acid lactose and phosphatidylserine. The composition is clear in sleep improvement effect, can effectively solve the problem of sleep maintenance caused by sleep deprivation, has the effects of protecting neural functions, improving memory and relieving anxiety from multiple dimensions, and can repair brain tissue damage and protect brain health. Based on the composition, products for assisting in improving memory, preventing and treating insomnia and anxiety, regulating neurodevelopmental disorders, protecting brain health and improving concentration can be developed, the health requirements of different people are comprehensively met, and the application value is high.

Described herein are isolated peptides, compositions comprising the same, and methods of using such peptides or compositions in the treatment of depression, central nervous system disorders, and neurodevelopmental disorders.

This disclosure belongs to the field of medical testing technology, and specifically relates to a classification, diagnostic, and prediction method, system, and electronic device for congenital neurodevelopmental disorders. Addressing the clinical diagnostic challenges of congenital neurodevelopmental disorders, this disclosure establishes for the first time a classification, diagnostic, and prediction method for congenital neurodevelopmental disorders based on whole-genome methylation signatures and customized SVM machine learning. This method achieves one-stop differential diagnosis across multiple mechanisms and diseases, filling a gap in existing technologies and providing a novel and efficient solution for the accurate diagnosis of congenital neurodevelopmental disorders.

A plurality of circular RNAs (circRNAs) the expression of which is correlated with brain disorders. The circRNAs are useful for compositions, kits, assays, and methods for the identification, diagnosis, screening, treatment and / or monitoring of brain disorders including psychiatric disorders such as bipolar disorder (BD), schizophrenia (SCZ), depression, Attention-Deficit / Hyperactivity Disorder (ADHD), Obsessive-compulsive disorder (OCD), Anxiety Disorders, etc., and neurodevelopmental disorders such as Autism, Asperger's Syndrome, and other Autism Spectrum Disorders (ASD), pervasive developmental disorders not otherwise specified (PDD-NOS), etc.

The invention provides a network science-based method for evaluating a herbicide neurodevelopmental toxicity risk. The herbicide which is widely used and is detected at high frequency in the environment is collected; acquiring a herbicide target and risk genes of neurodevelopment disorder related diseases; constructing a herbicide target network and a disease module; analyzing the neuro-developmental toxicity risk of the herbicide by network proximity; constructing an overlapping network of a herbicide target network and a disease module; screening core pathogenic genes based on multiple network topology algorithms and carrying out gene enrichment analysis; the toxicity risk is evaluated from the molecular level, and the high-risk herbicide variety is effectively discriminated. And a neuro-developmental toxic molecular mechanism of the herbicide is analyzed based on a network analysis system, so that a new framework from risk assessment to mechanism analysis is constructed for toxicity research of environmental chemicals.

The invention relates to the field of neurodevelopmental disorders, and discloses an electro-oculogram signal analysis and diagnosis system based on neurodevelopmental disorders, which extracts signal features from pre-processed electro-oculogram signals, and analyzes inter-group differences between signal features of a child patient group and signal features of a healthy child group. The method comprises the following steps: preliminarily screening out signal features with significant statistical difference between two groups, then carrying out severity correlation analysis on the screened signal features, screening and forming a feature list highly related to ADHD severity, and then comparing eye movement features of a child patient group under natural behaviors with eye movement features of a healthy child group, so as to obtain a feature list related to ADHD severity. The method comprises the following steps of: identifying and forming an abnormal signal feature list, fusing the feature list highly related to the ADHD severity and the abnormal signal feature list, calculating a comprehensive abnormal score, drawing an ROC curve according to the calculated comprehensive abnormal score, and carrying out grading evaluation on the ADHD severity of a child patient, so that accurate diagnosis and severity judgment on the ADHD disease are realized.

The present invention relates to a composition for treating or preventing neurodevelopmental disorders, particularly autism spectrum disorder, by selectively activating brain-resident regulatory T cells (Tregs). The present composition comprises IL-2 or an IL-2 gene (AAV-GFAP-IL-2) as an active ingredient, and induces Treg proliferation in the brain to alleviate neuroinflammation and improve behavioral defects.

The invention discloses a method for constructing a neurodevelopmental disorder animal model based on central nervous system myelin sheath function change and application, and belongs to the technical field of biological engineering. An Msl2 gene conditional knockout mouse model is constructed by adopting a gene engineering technology, the space-time specific knockout of a second exon of the Msl2 gene in a specific cell type is realized through a Cre-LoxP recombinase system, and the exon encodes a key enzyme activity region for catalyzing ubiquitination. Model construction is based on central nervous system oligodendrocyte / myelin sheath dysfunction, the behavior phenotype of the model is similar to the behavior of a typical neurodevelopment disorder animal, a brand new perspective is provided for exploring an etiology mechanism, model mice can be prepared on a large scale by performing directional mating on the gene modified mice, and the development of the model is promoted. And consistency of different experiment batches and reliable reproduction of experiment data are ensured.

Aspects of the present disclosure relate to expression cassettes encoding miniShank3 proteins, AAV vectors containing the expression cassettes, and gene therapy methods, particularly where the expression cassettes are formulated to further contain an AAV9 capsid, and the gene therapy is useful for treating neurodevelopmental disorders such as autism spectrum disorder (ASD) and Phelan-McDermid syndrome.

To provide a composition of trophinetide. [Solution] This disclosure describes a compound of formula (I), its stereoisomers, by-compounds, pharmaceutical compositions, and methods for producing such compounds using silylating agents, as well as methods for producing compositions and products produced using such methods. More specifically, this disclosure describes the production of trophinetides and by-products, compositions, and products containing such compounds for pharmaceutical applications for the treatment of neurodegenerative or neurodevelopmental disorders. JPEG2026063085000110.jpg55147

Described herein are antisense oligonucleotides (ASOs), vectors, and related compositions and methods for increasing endogenous expression of SHANK3 protein, and uses thereof in disorders associated with SHANK3 haploinsufficiency, such as Phelan-McDermid Syndrome.

The invention relates to therapeutic compositions for disorders associated with haploinsufficiency. The invention provides antisense oligonucleotides useful for treating neurodevelopmental disorders associated with mutations in the SYNGAP gene. The invention provides compositions that include synthetic antisense oligonucleotides (ASOs) that promote expression of the SynGAP protein by one or any combination of (i) preventing one or more miRNAs from interfering with production of the SynGAP protein; (ii) binding to 5′-UTR of the SYNGAP1 transcript and augmenting translation of the Syngap protein; and (iii) promoting RNAseH cleavage of antisense long non-coding RNAs that are anticorrelated with SYNGAP expression. When the composition is delivered to a patient with SYNGAP haploinsufficiency, the ASOs promote expression of the SynGAP protein.

Disclosed herein are systems for modifying nucleic acid splicing of a target RNA such as a SCN2A mRNA. The system may be useful in a method such as a method for treating a neurodevelopmental disorder. The system may include an expression system, or a modified small nuclear RNA (snRNA) that includes an exonic splicing silencer (ESS) sequence, and a target nucleic acid sequence that targets the target RNA.

Methods and systems for improving medical conditions by delivering a focused ultrasound signal to target sites of the brain. The focused ultrasound signal can have a mechanical index of between about 1.0 to about 8.0 and / or an acoustic pressure of between about 1.0 MPa to about 3.0 MPa. The medical condition can comprise addiction (including binge eating), anxiety disorders and anxiety associated disorders, tinnitus, neurodegenerative disorders, neuropsychiatric disorders, cognitive disorders, neurodevelopmental disorders, post-traumatic stress disorder, stroke recovery, and combinations thereof.

The invention discloses a method for constructing a social anomaly mouse model, relates to the technical field of animal model construction, and constructs a social anomaly model of a filial generation mouse by performing bisphenol S exposure on a female mouse in a pregnancy and nursing period. According to the mouse model constructed by the invention, in the pregnancy and nursing period, BPS is exposed, and the development of left secondary motor cortex neurons is damaged, so that progeny is induced to have social behavior disorder; the activity of neurons in the left M2 brain region is activated, so that social behavior disorders can be effectively relieved. The invention not only clarifies the neural development mechanism of the environmental endocrine disrupter-induced autism-like social disorder, but also provides a new thought of activating left M2 neurons as a potential intervention means, and can be used for developing drugs for treating the social behavior disorder induced by the environmental endocrine disrupter; the invention provides a new direction for etiological research and treatment strategy exploration of neurodevelopment disorder diseases taking social defects as core symptoms, and is beneficial to promoting deep development of related medical research.

This invention discloses a method for calculating a polygenic risk score (PRS or PRS score) for predicting autism and neurodevelopmental disorders (hereinafter collectively referred to as diseases). Its key feature is the improvement in the accuracy of predicting the relative risk of potential diseases by incorporating the genetic effects of rare variants (MAF < 0.1%) and common variants (MAF > 0.1%). This invention uses loss-of-function (LoF) rare variants detected by DNA sequencing (including but not limited to NGS / 3GS) to calculate gene-based PRS scores; and integrates these scores into existing snp-based PRS scores based solely on common variants detected by GWAS; thereby solving the problem of low variance interpretation (pseudo-R) in snp-based PRS scores calculated only based on common variants. 2 (and the problem of low predictive ability.)

The present invention generally relates to methods and systems for predicting one or more a kinetic biomarkers associated with one or more neurodevelopmental disorder, such as autism spectrum disorder, by monitoring and analysing various movement behaviours. Specifically, the present invention can be applied to monitor and record data on atypical movement behaviours, such as tiptoe behaviour and axis-spinning, when observed in subjects including children and adults. An aspect of the invention relates to a computer-implemented method for predicting a kinetic biomarker associated with a neurodevelopmental disorder; the method comprising: - receiving a first data flow indicative of a movement and orientation of the lower leg of the subject; - receiving a second data flow indicative of a movement and orientation of the foot of the subject; - determining using at least one machine learning model that the first data flow and second data flow correspond to an atypical movement event; - determining, based on a frequency of occurrence of the atypical movement event during a predetermined time window, that the first data flow and the second data flow correspond to at least one kinetic biomarker associated with the neurodevelopmental disorder; and, - generating a report comprising the kinetic biomarker.

The embodiment of the invention discloses a method and a device for identifying children with neurodevelopment disorder and electronic equipment. The method comprises the following steps: acquiring demographic statistics characteristics and intellectual index characteristics of to-be-identified children with normal intelligence; inputting the demographic statistical characteristics and the intellectual index characteristics of the to-be-identified children into a trained convergence identification model; the convergence recognition model is any one of the following machine learning models: a logistic regression model, a random forest model, a decision tree model or an extreme gradient boosting model; obtaining a target recognition result output by the convergence recognition model; the target recognition result indicates whether the to-be-recognized child has the neurodevelopment disorder or not. By implementing the embodiment of the invention, whether the children with normal intelligence have the neurodevelopment disorder problem or not can be automatically identified through the trained machine learning model in combination with the demographic characteristics and the intellectual index characteristics of the children, the accuracy is high, and the dependence on artificial experience is reduced.

Methods for target, biomarker, and patient selection discovery in central nervous system disorders utilizing patient-derived cellular models, spatial proteomics, and machine learning. The method generates neural cells from forebrain regions from induced pluripotent stem cells, performs cell-type specific proteome profiling using antibody-enzyme conjugates and spatial proteome profiling, and applies statistical data augmentation to sparse biological datasets. Machine learning classifiers with SHAP-based feature importance identify ranked biomarkers from mass spectrometry data. The platform enables patient stratification by linking molecular signatures to symptom severity, drug screening through biomarker modulation, and diagnostic applications. Kits comprising antibodies for biomarkers including antibodies for biomarkers identified by the method facilitate implementation. Applications include autism spectrum disorder, rare neurodevelopmental disorders, schizophrenia, epilepsy, Alzheimer's disease, and Parkinson's disease.

Provided in the present application is the use of betaine in preventing the occurrence of Autism Spectrum Disorder (ASD). Specifically, provided in the present application is the use of betaine or a pharmaceutically acceptable salt, stereoisomer, tautomer, nitrogen oxide, solvate, metabolite or prodrug thereof in the preparation of a drug. By using the betaine or the pharmaceutically acceptable salt, stereoisomer, tautomer, nitrogen oxide, solvate, metabolite or prodrug thereof as an active ingredient, the occurrence of ASD can be effectively prevented, fetal neurodevelopment can be optimized, or the risk of fetal neurodevelopmental disorders can be reduced.

Disease modification of specific neurodevelopmental disorders is demonstrated for preschool children through modulation of specific biogenic amine neurotransmitters and y-aminobutyric acid (GABA) / glutamine. In specific, cumulative reductions in maladaptive behaviors that interfere with activities of daily living for preschool populations are achieved through staged, long term, treatment. Additionally, a prophylaxis for certain neurodegenerative disorders is presented. Provided herein are compositions comprising digestive enzyme preparations and methods of using same for treating an Autism Spectrum Disorder (ASD).

Provided are oligomeric agents, methods, and pharmaceutical compositions for reducing the amount or activity of PACS1 RNA in a cell or a subject, and in certain instances reducing the amount of PACS1 protein in a cell or a subject. Such oligomeric agents, methods, and pharmaceutical compositions are useful to treat PACS1 neurodevelopmental disorder (PACS1-NDD).

The present disclosure provides methods of treating a neurodevelopmental disorder (NDD) in a subject by administering a therapeutically effective amount of N-acetyl leucine.

The present disclosure relates to the treatment and / or prevention of neurodevelopmental disorders, especially Autism Spectrum Disorders (ASD), using P2Y2 agonists such as: Diquafosol, Denufosol, MRS2698, MRS2768, PSB1114, ATP, ATP derivatives, UTP, UTP derivatives, 2-((ethyl(4-fluorobenzyl)amino)methyl)-7,8-dimethylquinolin-4(1H)-one, or a pharmaceutically acceptable salt or solvate thereof. Also disclosed herein are combination therapies, compositions, and kits for the treatment and / or prevention of neurodevelopmental disorders using said P2Y2 agonists.

The invention discloses application of Trolox in preparation of a medicine for treating neurodevelopment disorder related diseases, and belongs to the technical field of biological medicine. The invention firstly discovers that Trolox has new application of drugs for preventing and / or treating neurodevelopment disorder related diseases; furthermore, the Trolox restores the neural connectivity by repairing the densities of the damaged neuron dendritic spines of the brain hippocampus and / or striatum; abnormal dopaminergic signal channels are corrected, so that expression of key receptors and downstream molecules thereof is recovered to be normal, and therefore, diseases related to neurodevelopment disorders are prevented and / or treated; the neuroprotective effect of Trolox depends on the activation of dopamine D1 and D2 receptor pathways; in addition, the invention discloses the potential of Trolox in the aspect of targeted repair of the core pathology link of the neurodevelopmental disorder for the first time, and a clear candidate compound and an action target are provided for developing a novel medicine for treating the diseases.

Provided are platforms, methods, and systems to customize virtual or augmented reality (collectively, XR) content for an individual or a group of individuals, such as to treat a user having a mental or neurodevelopmental disorder (e.g., autism), train or educate an individual (e.g., student) or a group of individuals, or otherwise attend to a special need of an individual or a group of individuals. A graphical user interface may be used to edit the XR content.

The present invention provides methods for treating a genetic neurodevelopmental disorder such as Rett syndrome, comprising administering to a subject in need thereof a liquid oral dosage formulation comprising a therapeutically effective amount of ANAVEX2-73.

This application pertains to a compound of Formula (I), Formula (I'), Formula (I") or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein X, R1, R2, R3, R5, R6, and R7 are as defined herein, and uses of such compounds in methods of treating neurodegenerative diseases, neurodevelopmental disorders, and age-related memory impairment.